Molecular genetics of coronary artery disease

Journal of Human Genetics

Volumn 61, Issue 1, 2016, Pages 71-77

  Ozaki, Kouichi ^a   Tanaka, Toshihiro ^a,b  

^a Institute of Physical and Chemical Research   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2B; GALECTIN 2; LYMPHOTOXIN; PROTEASOME; PROTEASOME SUBUNIT ALPHA TYPE 6; UNCLASSIFIED DRUG; BRAP PROTEIN, HUMAN; LGALS2 PROTEIN, HUMAN; PSMA6 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

BRAP GENE; CHROMOSOME 6P; CORONARY ARTERY DISEASE; EXPRESSION QUANTITATIVE TRAIT LOCUS; GENE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE MAPPING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC RISK; GENETIC VARIABILITY; HEART INFARCTION; HEREDITY; HUMAN; INTRACELLULAR SIGNALING; JAPANESE (PEOPLE); MOLECULAR GENETICS; NEXT GENERATION SEQUENCING; PROTEIN ANALYSIS; PROTEIN INTERACTION; QUANTITATIVE TRAIT LOCUS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY;

CORONARY ARTERY DISEASE; GALECTIN 2; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LYMPHOTOXIN-ALPHA; MYOCARDIAL INFARCTION; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN-PROTEIN LIGASES;

EID: 84955462369     PISSN: 14345161     EISSN: 1435232X     Source Type: Journal    
DOI: 10.1038/jhg.2015.70     Document Type: Review

References (97)

1. Breslow, J. W. Cardiovascular disease burden increases, NIH funding decreases. Nat. Med. 3, 600-601 (1997).
2. Braunwald, E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns and opportunities. N. Engl. J. Med. 337, 1360-1369 (1997).
3. Falk, E. S., Hah, P. K., & Fuster, V. Coronary plaque disruption. Circulation 92, 657-671 (1995).
4. Libby, P. Molecular bases of the acute coronary syndromes. Circulation 91, 2844-2850 (1995).
5. Ross, R. Atherosclerosis-An inflammatory disease. N. Engl. J. Med. 340, 115-126 (1999).
6. Peden, J. F., & Farrall, M. Thirty-five common variants for coronary artery disease: the fruits of much collaborative labour. Hum. Mol. Genet. 20, R198-R205 (2011).
7. Roberts, R., & Stewart, A. F. Genes and coronary artery disease. J. Am. Col. Cardiol. 60, 1715-1721 (2012).
8. Lander, E S. The new genomics: global views of biology. Science 274, 536-539 (1996).
9. Risch, N., & Merikangas, K. The future of genetic studies of complex human diseases. Science 273, 1516-1517 (1996).
10. Collins, F. S., Guyer, M. S., & Charkravarti, A. Variations on a theme: cataloging human DNA sequence variation. Science 278, 1580-1581 (1997).
11. Haga, H., Yamada, R., Ohnishi, Y., Nakamura, Y., & Tanaka, T. Gene-based SNP discovery as part of the Japanese Millennium Genome project: identification of 190, 562 genetic variations in the human genome. J. Hum. Genet. 47, 605-610 (2002).
12. Ohnishi, Y., Tanaka, T., Ozaki, K., Yamada, R., Suzuki, H., & Nakamura, Y. A highthroughput SNP typing system for genomewide association studies. J. Hum. Genet. 46, 471-477 (2001).
13. Ozaki, K., Ohnishi, Y., Iida, A., Sekine, A., Yamada, R., Tsunoda, T., et al. Functional SNPs in the lymphotoxin-Alpha gene that are associated with susceptibility to myocardial infarction. Nat. Genet. 32, 650-654 (2002).
14. Ishii, N., Ozaki, K., Sato, H., Mizuno, H., Saito, S., Takahashi, A., et al. Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. J. Hum. Genet. 51, 1087-1099 (2006).
15. Ebana, Y., Ozaki, K., Inoue, K., Sato, H., Iida, A., Lwin, H., et al. A functional SNP in ITIH3 is associated with susceptibility to myocardial infarction. J. Hum. Genet. 52, 220-229 (2007).
16. Ozaki, K., Inoue, K., Sato, H., Iida, A., Ohnishi, Y., Sekine, A., et al. Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-Alpha secretion in vitro. Nature 429, 72-75 (2004).
17. Ozaki, K., Sato, H., Iida, A., Iida, A., Ohnishi, Y., Sekine, A., et al. A functional SNP in PSMA6 confers risk of myocardial infarction in the Japanese population. Nat. Genet. 38, 921-225 (2006).
18. Ozaki, K., Sato, H., Inoue, K., Tsunoda, T., Sakata, Y., Mizuno, H., et al. SNPs in BRAP associated with risk of myocardial infarction in Asian populations. Nat. Genet. 41, 329-333 (2009).
19. International HapMap Consortium. A haplotype map of the human genome. Nature 437, 1299-1320 (2005).
20. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14, 000 cases of seven common diseases and 3, 000 shared controls. Nature 447, 661-678 (2007).
21. Helgadottir, A., Thorleifsson, G., Magnusson, K. P., Grétarsdottir, S., Steinthorsdottir, V., Manolescu, A., et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316, 1491-1493 (2007).
22. McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A., Roberts, R., Cox, D. R., et al. A common allele on chromosome 9 associated with coronary heart disease. Science 316, 1488-1491 (2007).
23. Samani, N. J., Erdmann, J., Hall, A. S., Hengstenberg, C., Mangino, M., Mayer, B., et al. Genome wide association analysis of coronary artery disease. N. Engl. J. Med. 357, 443-543 (2007).
24. Erdmann, J., Grosshennig, A., Braund, P. S., König, I. R., Hengstenberg, C., Hall, A. S., et al. New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat. Genet. 41, 280-282 (2009).
25. Myocardial Infarction Genetics Consortium. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat. Genet. 41, 334-341 (2009).
26. Gudbjartsson, D. F., Bjornsdottir, U. S., Halapi, E., Helgadottir, A., Sulem, P., Jonsdottir, G. M., et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat. Genet. 41, 342-347 (2009).
27. Trégouët, D. A., König, I. R., Erdmann, J., Munteanu, A., Braund, P. S., Hall, A. S., et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat. Genet. 41, 283-285 (2009).
28. Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361, 2518-2528 (2009).
29. The Coronary Artery Disease (C4D) Genetics Consortium. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat. Genet. 43, 339-344 (2011).
30. Reilly, M. P., Li, M., He, J., Ferguson, J. F., Stylianou, I. M., Mehta, N. N., et al. Identification of ADAMT7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome wide association studies. Lancet 377, 382-392 (2011).
31. Schunkert, H., König, I. R., Kathiresan, S., Reilly, M. P., Assimes, T. L., Holm, H., et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat. Genet. 43, 333-338 (2011).
32. Wang, F., Xu, C. Q., He, Q., Cai, J. P., Li, X. C., Wang, D., et al. Genome-wide association identifies a susceptibility locus for coronary artery disease in the Chinese Han population. Nat. Genet. 43, 345-349 (2011).
33. Aoki, A., Ozaki, K., Sato, H., Takahashi, A., Kubo, M., Sakata, Y., et al. SNPs on 5p15.3 associated with myocardial infarction in Japanese population. J. Hum. Genet. 56, 47-51 (2011).
34. Yamada, Y., Nishida, T., Ichihara, S., Sawabe, M., Fuku, N., Nishigaki, Y., et al. Association of a polymorphism of BTN2A1 with myocardial infarction in East Asian populations. Atherosclerosis 215, 145-152 (2011).
35. IBC 50 K CAD Consortium. Large-scale gene-centric analysis identifies novel variants for coronary artery disease. PLoS Genet. 7, e1002260 (2011).
36. Takeuchi, F., Yokota, M., Yamamoto, K., Nakashima, E., Katsuya, T., Asano, H., et al. Genome-wide association study of coronary artery disease in the Japanese. Eur. J. Hum. Genet. 20, 333-340 (2012).
37. The CARDIoGRAMplusC4D Consortium. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat. Genet. 45, 25-33 (2013).
38. Hirokawa, M., Morita, H., Tajima, T., Takahashi, A., Ashikawa, K., Miya, F., et al. A genome-wide association study identifies PLCL2 and AP3D1-DOT1L-SF3A2 as new susceptibility loci for myocardial infarction in Japanese. Eur. J. Hum. Genet. 23, 374-380 (2014).
39. Ozaki, K., & Tanaka, T. Genome-wide association study to identify SNPs conferring risk of myocardial infarction and their functional analyses. Cell. Mol. Life Sci. 62, 1804-1813 (2005).
40. Tanaka, T., & Ozaki, K. Inflammation as a risk factor for myocardial infarction. J. Hum. Genet. 51, 595-604 (2006).
41. PROCARDIS Consortium. A trio family study showing association of the lymphotoxinalpha N26 (804 A) allele with coronary artery disease. Eur. J. Hum. Genet. 12, 770-774 (2004).
42. Lian, J., Fang, P., Dai, D., Ba, Y., Yang, X., Huang, X., et al. Association between LGALS2 3279C4T and coronary artery disease: a case-control study and a metaanalysis. Biomed. Rep. 2, 879-885 (2014).
43. Beinke, S., & Ley, S. C. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem. J. 382, 393-409 (2004).
44. Coux, O., Tanaka, K., & Goldberg, A. L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 65, 801-847 (1996).
45. Liu, X., Wang, X., Shen, Y., Wu, L., Ruan, X., Lindpaintner, K., et al. The functional variant rs1048990 in PSMA6 is associated with susceptibility to myocardial infarction in a Chinese population. Atherosclerosis 206, 199-203 (2009).
46. Karin, M., & Delhase, M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin. Immunol. 12, 85-98 (2000).
47. Li, S., Ku, C. Y., Farmer, A. A., Cong, Y. S., Chen, C. F., & Lee, W. H. Identification of a novel cytoplasmic protein that specifically binds to nuclear localization signal motifs. J. Biol. Chem. 273, 6183-6189 (1998).
48. Matheny, S. A., Chen, C., Kortum, R. L., Razidlo, G. L., Lewis, R. E., White, M. A., et al. Ras regulates assembly of mitogenic signalling complexes through the effector protein IMP. Nature 427, 256-260 (2004).
49. Ory, S., & Morrison, D. K. Signal transduction: implications for Ras-dependent ERK signaling. Curr. Biol. 14, R277-R278 (2004).
50. O'Neill, L. A. Targeting signal transduction as a strategy to treat inflammatory diseases. Nat. Rev. Drug Discov. 5, 549-563 (2006).
51. Liao, Y. C., Wang, Y. S., Guo, Y. C., Ozaki, K., Tanaka, T., Lin, H. F., et al. BRAP activates the inflammatory cascades and increases the risk for carotid atherosclerosis. Mol. Med. 17, 1065-1074 (2011).
52. Manolio, T A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., & Hunter, D. J. Finding the missing heritability of complex diseases. Nature 461, 747-753 (2009).
53. Hinohara, K., Nakajima, T., Takahashi, M., Hohda, S., Sasaoka, T., Nakahara, K., et al. Replication of the association between a chromosome 9p21 polymorphism and coronary artery disease in Japanese and Korean populations. J. Hum. Genet. 53, 357-359 (2008).
54. Shen, G. Q., Li, L., Rao, S., Abdullah, K. G., Ban, J. M., Lee, B. S., et al. Four SNPs on chromosome 9p21 in a South Korean population implicate a genetic locus that confers high cross-race risk for development of coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 28, 360-365 (2008).
55. Ding, H., Xu, Y., Wang, X., Wang, Q., Zhang, L., Tu, Y., et al. 9p21 is a shared susceptibility locus strongly for coronary artery disease and weakly for ischemic stroke in Chinese Han population. Circ. Cardiovasc. Genet. 2, 338-346 (2009).
56. Kumar, J., Yumnam, S., Basu, T., Ghosh, A., Garg, G., Karthikeyan, G., et al. Association of polymorphisms in 9p21 region with CAD in North Indian population: replication of SNPs identified through GWAS. Clin. Genet. 79, 588-593 (2011).
57. Saleheen, D., Alexander, M., Rasheed, A., Wormser, D., Soranzo, N., Hammond, N., et al. Association of the 9p21.3 locus with risk of first-ever myocardial infarction in Pakistanis: case-control study in South Asia and updated meta-Analysis of Europeans. Arterioscler. Thromb. Vasc. Biol. 30, 1467-1473 (2010).
58. Assimes, T. L., Knowles, J. W., Basu, A., Iribarren, C., Southwick, A., Tang, H., et al. Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. Hum. Mol. Genet. 17, 2320-2328 (2008).
59. Kral, B. G., Mathias, R. A., Suktitipat, B., Ruczinski, I., Vaidya, D., Yanek, L. R., et al. A common variant in the CDKN2B gene on chromosome 9p21 protects against coronary artery disease in Americans of African ancestry. J. Hum. Genet. 56, 224-229 (2011).
60. Roberts, R. Genetics of coronary artery disease: an update. Methodist Debakey Cardiovasc. J. 10, 7-12 (2014).
61. Palomaki, G E., Melillo, S., & Bradley, L. A. Association between 9p21 genomic markers and heart disease: a meta-Analysis. JAMA 303, 648-656 (2010).
62. Scott, L. J., Mohlke, K. L., Bonnycastle, L. L., Willer, C. J., Li, Y., Duren, W. L., et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316, 1341-1345 (2007).
63. Zeggini, E., Weedon, M. N., Lindgren, C. M., Frayling, T. M., Elliott, K. S., Lango, H., et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316, 1336-1341 (2007).
64. Saxena, R., Voight, B. F., Lyssenko, V, Burtt, N. P., De Bakker, P. I., et al. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316, 1331-1336 (2007)
65. Helgadottir, A., Thorleifsson, G., Magnusson, K. P., Grétarsdottir, S., Steinthorsdottir, V., Manolescu, A., et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat. Genet. 40, 217-224 (2008).
66. Emanuele, E., Lista, S., Ghidoni, R., Binetti, G., Cereda, C., Benussi, L., et al. Chromosome 9p21.3 genotype is associated with vascular dementia and Alzheimer?s disease. Neurobiol. Aging 32, 1231-1235 (2011).
67. Assimes, T. L., Knowles, J. W., Basu, A., Iribarren, C., Southwick, A., & Tang, H. Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multiethnic ADVANCE study. Hum. Mol. Genet. 17, 2320-2328 (2008).
68. O?Donnell, C. J., Kavousi, M., Smith, A. V., Kardia, S. L., Feitosa, M. F., Hwang, S. J., et al. Genomewide association study for coronary artery calcification with follow-up in myocardial infarction. Circulation 124, 2855-2864 (2011)
69. Murabito, J. M., White, C. C., Kavousi, M., Sun, Y. V., Feitosa, M. F., & Nambi, V. Association between chromosome 9p21 variants and the ankle-brachial index identified by a meta-Analysis of 21 genome-wide association studies. Circ. Cardiovasc. Genet. 5, 100-112 (2012).
70. Johnson, A. D., Hwang, S. J., Voorman, A., Morrison, A., Peloso, G. M., & Hsu, Y. H. Resequencing and clinical associations of the 9p21.3 region: a comprehensive investigation in the Framingham heart study. Circulation 127, 799-810 (2013).
71. Bishop, D. T., Demenais, F., Iles, M. M., Harland, M., Taylor, J. C., & Corda, E. Genomewide association study identifies three loci associated with melanoma risk. Nat. Genet. 41, 920-925 (2009).
72. Wrensch, M., Jenkins, R. B., Chang, J. S., Yeh, R. F., Xiao, Y., & Decker, P. A. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat. Genet. 41, 905-908 (2009).
73. Jarinova, O., Stewart, A. F. R., Roberts, R., Wells, G., Lau, P., Naing, T., et al. Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler. Thromb. Vasc. Biol. 29, 1671-1677 (2009).
74. Liu, Y., Sanoff, H. K., Cho, H., Burd, C. E., Torrice, C., Mohlke, K. L., et al. INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS One 4, e5027 (2009).
75. Cunnington, M. S., Santibanez Koref, M., Mayosi, B. M., Burn, J., & Keavney, B. Chromosome 9p21 SNPs associated with multiple disease phenotypes correlate with ANRIL expression. PLoS Genet. 6, e1000899 (2010).
76. McPherson, R. Chromosome 9p21.3 locus for coronary artery disease: how little we know. J. Am. Coll. Cardiol. 62, 1382-1383 (2013).
77. Harismendy, O., Notani, D., Song, X., Rahim, N. G., Tanasa, B., Heintzman, N., et al. 9p21 DNA variants associated with coronary artery disease impair interferon-gamma signalling response. Nature 470, 264-268 (2011).
78. Almontashiri, N. A., Fan, M., Cheng, B. L., Chen, H. H., Roberts, R., & Stewart, A. F. J. Am. Coll. Cardiol. 61, 143-147 (2013).
79. Erridge, C., Gracey, J., Braund, P. S., & Samani, N. J. The 9p21 locus does not affect risk of coronary artery disease through induction of type 1 interferons. J. Am. Coll. Cardiol. 62(15) 1376-1381
80. Qi, L., Cornelis, M. C., Kraft, P., Jensen, M., Van Dam, R. M., Sun, Q., et al. Genetic variants in ABO blood group region, plasma soluble E-selectin levels and risk of type 2 diabetes. Hum. Mol. Genet. 19, 1856-1862 (2010).
81. Chasman, D. I., Pare, G., Mora, S., Hopewell, J. C., Peloso, G., Clarke, R., et al. Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet. 5, e1000730 (2009).
82. Pare, G., Chasman, D. I., Kellogg, M., Zee, R. Y., Rifai, N., Badola, S., et al. Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genomewide association study of 6, 578 women. PLoS Genet. 4, e1000118 (2008).
83. Paterson, A. D., Lopes-Virella, M. F., Waggott, D., Boright, A. P., Hosseini, S. M., Carter, R. E., et al. Genome-wide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin. Arterioscler. Thromb. Vasc. Biol. 29, 1958-1967 (2009)
84. Barbalic, M., Dupuis, J., Dehghan, A., Bis, J. C., Hoogeveen, R. C., Schnabel, R. B., et al. Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum. Mol. Genet. 19, 1863-1872 (2010).
85. Bampali, K., Mouzarou, A., Lamnisou, K., & Babalis, D. Genetics and coronary artery disease: present and future. Hellenic. J. Cardiol. 55, 156-163 (2013).
86. Abifadel, M., Varret, M., Rabeè, J. D., Allard, D., Ouguerram, K., Devillers, M., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154-156 (2003).
87. Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366, 1108-1118 (2012).
88. Stein, E. A., Gipe, D., Bergeron, J., Gaudet, D., Weiss, R., Dufour, R., et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 380, 29-36 (2012).
89. Stroes, E., Colquhoun, D., Sullivan, D., Civeira, F., Rosenson, R. S., Watts, G. F., et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J. Am. Coll. Cardiol. 63, 2541-2548 (2014).
90. Raal, F. J., Stein, E. A., Dufour, R., Turner, T., Civeira, F., Burgess, L., et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 385, 331-340 (2015).
91. Moriarty, P. M., Jacobson, T. A., Bruckert, E., Thompson, P. D., Guyton, J. R., Baccara-Dinet, M. T., et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J. Clin. Lipidol. 8, 554-561
92. Park, S. W., Moon, Y. A., & Horton, J. D. Posttranscriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem. 279, 50630-50638 (2004).
93. Maxwell, K. N., & Breslow, J. L. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl Acad. Sci. USA 101, 7100-7105 (2004).
94. Turpeinen, H., Raitoharju, E., Oksanen, A., Oksala, N., Levula, M., & Lyytikäinen, L P. Proprotein convertases in human atherosclerotic plaques: the overexpression of FURIN and its substrate cytokines BAFF and APRIL. Atherosclerosis 219, 799-806 (2011).
95. Crosby, J., Pelso, G. M., Auer, P. L., Crosslin, D. R., Stitziel, N. O., et al. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N. Engl. J. Med. 371, 22-31 (2014)
96. Do, R., Stitziel, N. O., Won, H. H., Jørgensen, A. B., Duga, S., & Angelica Merlini, P. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 518, 102-106 (2015).
97. Erdmann, J., Stark, K., Esslinger, U. B., Rumpf, P. M., Koesling, D., De Wit, C., et al. Dysfunctional nitric oxide signalling increases risk of myocardial infarction. Nature 504, 432-436 (2013).